GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zoetis Inc (NYSE:ZTS) » Definitions » Cyclically Adjusted PS Ratio

Zoetis (Zoetis) Cyclically Adjusted PS Ratio : 10.42 (As of Apr. 28, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Zoetis Cyclically Adjusted PS Ratio?

As of today (2024-04-28), Zoetis's current share price is $158.42. Zoetis's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $15.21. Zoetis's Cyclically Adjusted PS Ratio for today is 10.42.

The historical rank and industry rank for Zoetis's Cyclically Adjusted PS Ratio or its related term are showing as below:

ZTS' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 9.58   Med: 12.98   Max: 19.62
Current: 10.42

During the past years, Zoetis's highest Cyclically Adjusted PS Ratio was 19.62. The lowest was 9.58. And the median was 12.98.

ZTS's Cyclically Adjusted PS Ratio is ranked worse than
93.34% of 736 companies
in the Drug Manufacturers industry
Industry Median: 2.06 vs ZTS: 10.42

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Zoetis's adjusted revenue per share data for the three months ended in Dec. 2023 was $4.810. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $15.21 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Zoetis Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Zoetis's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zoetis Cyclically Adjusted PS Ratio Chart

Zoetis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 14.64 19.24 10.41 12.98

Zoetis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.41 11.51 11.63 11.51 12.98

Competitive Comparison of Zoetis's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Zoetis's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zoetis's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zoetis's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Zoetis's Cyclically Adjusted PS Ratio falls into.



Zoetis Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Zoetis's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=158.42/15.21
=10.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zoetis's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Zoetis's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=4.81/129.4194*129.4194
=4.810

Current CPI (Dec. 2023) = 129.4194.

Zoetis Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 2.191 99.695 2.844
201406 2.308 100.560 2.970
201409 2.408 100.428 3.103
201412 2.623 99.070 3.427
201503 2.190 99.621 2.845
201506 2.349 100.684 3.019
201509 2.420 100.392 3.120
201512 2.545 99.792 3.301
201603 2.326 100.470 2.996
201606 2.422 101.688 3.083
201609 2.492 101.861 3.166
201612 2.572 101.863 3.268
201703 2.485 102.862 3.127
201706 2.569 103.349 3.217
201709 2.736 104.136 3.400
201712 2.974 104.011 3.701
201803 2.789 105.290 3.428
201806 2.903 106.317 3.534
201809 3.047 106.507 3.702
201812 3.228 105.998 3.941
201903 3.012 107.251 3.635
201906 3.208 108.070 3.842
201909 3.290 108.329 3.931
201912 3.486 108.420 4.161
202003 3.203 108.902 3.806
202006 3.238 108.767 3.853
202009 3.732 109.815 4.398
202012 3.774 109.897 4.444
202103 3.915 111.754 4.534
202106 4.084 114.631 4.611
202109 4.178 115.734 4.672
202112 4.136 117.630 4.551
202203 4.189 121.301 4.469
202206 4.352 125.017 4.505
202209 4.268 125.227 4.411
202212 4.371 125.222 4.518
202303 4.305 127.348 4.375
202306 4.709 128.729 4.734
202309 4.662 129.860 4.646
202312 4.810 129.419 4.810

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Zoetis  (NYSE:ZTS) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Zoetis Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Zoetis's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Zoetis (Zoetis) Business Description

Industry
Address
10 Sylvan Way, Parsippany, NJ, USA, 07054
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Executives
Roxanne Lagano officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Kristin C Peck officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Heidi C. Chen officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Robert J Polzer officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Soria Ester Banque officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Rimma Driscoll officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Jamie Brannan officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Vanessa Broadhurst director ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Willie M Reed director C/O ZOETIS, 100 CAMPUS DRIVE, FLORHAM PARK NJ 07932
Nicholas Ashton officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Roman Trawicki officer: Executive Vice President C/O ZOETIS INC., 100 CAMPUS DRIVE, FLORHAM PARK NJ 07932
Glenn David officer: SVP and Acting CFO C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Astorga Jeannette Ferran officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Catherine A. Knupp officer: Executive Vice President C/O ZOETIS INC., 100 CAMPUS DRIVE, FLORHAM PARK NJ 07940
Gregory Norden director 16640 CHESTERFIELD GROVE DRIVE, SUITE 200, CHESTERFIELD MO 63005

Zoetis (Zoetis) Headlines

From GuruFocus

Q2 2022 Zoetis Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Zoetis Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-23-2024

Q1 2022 Zoetis Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2021 Zoetis Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2022 Zoetis Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Zoetis Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 01-23-2024

Zoetis Inc at Cowen Health Care Conference Transcript

By GuruFocus Research 01-23-2024